S&P 500   3,982.21 (+0.28%)
DOW   32,464.49 (+0.70%)
QQQ   308.16 (-0.88%)
AAPL   158.31 (-1.21%)
MSFT   276.05 (-1.61%)
META   201.49 (-2.19%)
GOOGL   102.27 (-3.01%)
AMZN   97.34 (-0.81%)
TSLA   192.27 (+0.98%)
NVDA   264.11 (-1.37%)
NIO   8.93 (-1.54%)
BABA   85.82 (-1.24%)
AMD   95.95 (-2.04%)
T   18.83 (+1.18%)
F   11.52 (+0.09%)
MU   59.53 (-2.67%)
CGC   1.89 (-0.62%)
GE   92.81 (+1.58%)
DIS   94.64 (+0.60%)
AMC   4.33 (-3.13%)
PYPL   73.48 (-0.54%)
PFE   40.30 (-0.22%)
NFLX   328.58 (+0.06%)
S&P 500   3,982.21 (+0.28%)
DOW   32,464.49 (+0.70%)
QQQ   308.16 (-0.88%)
AAPL   158.31 (-1.21%)
MSFT   276.05 (-1.61%)
META   201.49 (-2.19%)
GOOGL   102.27 (-3.01%)
AMZN   97.34 (-0.81%)
TSLA   192.27 (+0.98%)
NVDA   264.11 (-1.37%)
NIO   8.93 (-1.54%)
BABA   85.82 (-1.24%)
AMD   95.95 (-2.04%)
T   18.83 (+1.18%)
F   11.52 (+0.09%)
MU   59.53 (-2.67%)
CGC   1.89 (-0.62%)
GE   92.81 (+1.58%)
DIS   94.64 (+0.60%)
AMC   4.33 (-3.13%)
PYPL   73.48 (-0.54%)
PFE   40.30 (-0.22%)
NFLX   328.58 (+0.06%)
S&P 500   3,982.21 (+0.28%)
DOW   32,464.49 (+0.70%)
QQQ   308.16 (-0.88%)
AAPL   158.31 (-1.21%)
MSFT   276.05 (-1.61%)
META   201.49 (-2.19%)
GOOGL   102.27 (-3.01%)
AMZN   97.34 (-0.81%)
TSLA   192.27 (+0.98%)
NVDA   264.11 (-1.37%)
NIO   8.93 (-1.54%)
BABA   85.82 (-1.24%)
AMD   95.95 (-2.04%)
T   18.83 (+1.18%)
F   11.52 (+0.09%)
MU   59.53 (-2.67%)
CGC   1.89 (-0.62%)
GE   92.81 (+1.58%)
DIS   94.64 (+0.60%)
AMC   4.33 (-3.13%)
PYPL   73.48 (-0.54%)
PFE   40.30 (-0.22%)
NFLX   328.58 (+0.06%)
S&P 500   3,982.21 (+0.28%)
DOW   32,464.49 (+0.70%)
QQQ   308.16 (-0.88%)
AAPL   158.31 (-1.21%)
MSFT   276.05 (-1.61%)
META   201.49 (-2.19%)
GOOGL   102.27 (-3.01%)
AMZN   97.34 (-0.81%)
TSLA   192.27 (+0.98%)
NVDA   264.11 (-1.37%)
NIO   8.93 (-1.54%)
BABA   85.82 (-1.24%)
AMD   95.95 (-2.04%)
T   18.83 (+1.18%)
F   11.52 (+0.09%)
MU   59.53 (-2.67%)
CGC   1.89 (-0.62%)
GE   92.81 (+1.58%)
DIS   94.64 (+0.60%)
AMC   4.33 (-3.13%)
PYPL   73.48 (-0.54%)
PFE   40.30 (-0.22%)
NFLX   328.58 (+0.06%)
NASDAQ:VRNA

Verona Pharma - VRNA Stock Forecast, Price & News

$20.63
0.00 (0.00%)
(As of 03/27/2023 12:02 PM ET)
Add
Compare
Today's Range
$20.38
▼
$21.10
50-Day Range
$18.06
▼
$23.92
52-Week Range
$3.41
▼
$26.44
Volume
153,836 shs
Average Volume
587,940 shs
Market Capitalization
$1.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.33

Verona Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
40.6% Upside
$29.33 Price Target
Short Interest
Healthy
2.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.17mentions of Verona Pharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$2.79 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.90) to ($0.91) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

404th out of 995 stocks

Pharmaceutical Preparations Industry

185th out of 482 stocks

See Top Rated MarketRank™ Stocks Here

VRNA stock logo

About Verona Pharma (NASDAQ:VRNA) Stock

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Receive VRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter.

VRNA Stock News Headlines

March 27, 2023 | seekingalpha.com
Verona's Ensifentrine: A Promising Novel Treatment For COPD Patients
March 23, 2023 | americanbankingnews.com
BTIG Research Boosts Verona Pharma (NASDAQ:VRNA) Price Target to $31.00
March 27, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
March 22, 2023 | finance.yahoo.com
Verona Pharma PLC American Depositary Share (VRNA) Stock Moves -0.46%: What You Should Know
March 17, 2023 | americanbankingnews.com
HC Wainwright Equities Analysts Decrease Earnings Estimates for Verona Pharma plc (NASDAQ:VRNA)
March 13, 2023 | msn.com
4 Analysts Have This to Say About Verona Pharma
March 13, 2023 | markets.businessinsider.com
H.C. Wainwright Reaffirms Their Buy Rating on Verona Pharma (VRNA)
March 9, 2023 | finance.yahoo.com
Verona Pharma plc (NASDAQ:VRNA) Q4 2022 Earnings Call Transcript
March 27, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
March 8, 2023 | bizjournals.com
Raleigh drugmaker eyes regulatory push for COPD treatment
March 7, 2023 | finanznachrichten.de
Verona Pharma plc: Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 7, 2023 | finance.yahoo.com
Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 6, 2023 | msn.com
Earnings Preview For Verona Pharma
March 1, 2023 | finance.yahoo.com
Verona Pharma plc (NASDAQ:VRNA) is definitely on the radar of institutional investors who own 39% of the company
February 23, 2023 | finance.yahoo.com
Verona Pharma PLC American Depositary Share (VRNA) Gains But Lags Market: What You Should Know
February 21, 2023 | finance.yahoo.com
Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
February 15, 2023 | finance.yahoo.com
Verona (VRNA) to Report Q4 Earnings: What's in the Cards?
February 14, 2023 | finance.yahoo.com
Verona Pharma PLC American Depositary Share (VRNA) Gains As Market Dips: What You Should Know
February 1, 2023 | seekingalpha.com
Verona: Second Successful Phase 3 Moves The Needle Forward
January 17, 2023 | finance.yahoo.com
Verona Pharma PLC American Depositary Share (VRNA) Dips More Than Broader Markets: What You Should Know
January 10, 2023 | finance.yahoo.com
Verona Pharma PLC American Depositary Share (VRNA) Stock Sinks As Market Gains: What You Should Know
December 30, 2022 | finance.yahoo.com
4 Drug Stocks That More Than Doubled This Year
December 20, 2022 | msn.com
Hot Stocks: TSLA sets another new 52-week low; FCEL drops on earnings; DLO, VRNA rose
December 20, 2022 | msn.com
BTIG Maintains Buy Rating for Verona Pharma: Here's What You Need To Know
December 20, 2022 | finance.yahoo.com
Verona Pharma Stock Garners Investors' Attention After Successful COPD Trial
December 20, 2022 | finance.yahoo.com
Top-Notch Verona Pharma Scores A Win In COPD — And Hits A Four-Year High
December 20, 2022 | finance.yahoo.com
Raleigh drugmaker's stock jumps on positive results for lung disease treatment
See More Headlines
Receive VRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter.

VRNA Company Calendar

Last Earnings
3/07/2023
Today
3/27/2023
Next Earnings (Estimated)
5/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VRNA
CUSIP
N/A
CIK
1657312
Web
www.veronapharma.com
Phone
011-44-0-2032834200
Fax
N/A
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$29.33
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+42.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.12)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-68,700,000.00
Net Margins
N/A
Pretax Margin
-14,944.98%
Return on Equity
-38.97%
Return on Assets
-32.01%

Debt

Debt-to-Equity Ratio
0.04
Current Ratio
12.77
Quick Ratio
12.77

Sales & Book Value

Annual Sales
$460,000.00
Price / Sales
3,391.39
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.05 per share
Price / Book
6.76

Miscellaneous

Outstanding Shares
75,620,000
Free Float
72,674,000
Market Cap
$1.56 billion
Optionable
Not Optionable
Beta
0.13

Key Executives

  • Dr. David S. ZaccardelliDr. David S. Zaccardelli (Age 57)
    Pres, CEO & Exec. Director
    Comp: $627.27k
  • Mr. Mark W. HahnMr. Mark W. Hahn (Age 59)
    Chief Financial Officer
    Comp: $639.08k
  • Dr. Kathleen A. Rickard (Age 64)
    Chief Medical Officer
    Comp: $562.38k
  • Ms. Claire Louise Poll L.C.S.W. (Age 55)
    B.A., B Juris, LLB, ASIA, Gen. Counsel
  • Ms. Victoria Stewart
    Director of Communications
  • Mr. Matthew Casbon
    VP of Sales, Marketing & Training
  • Ms. Ostra Jewell
    Sr. VP of HR
  • Dr. Peter Spargo (Age 60)
    Sr. VP of Chemistry Manufacturing & Controls
  • Dr. Tara Rheault M.P.H. (Age 45)
    Ph.D., Sr. VP of R&D
  • Ms. Nina Church
    Exec. Director of Global Clinical Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













VRNA Stock - Frequently Asked Questions

Should I buy or sell Verona Pharma stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRNA shares.
View VRNA analyst ratings or view top-rated stocks.

What is Verona Pharma's stock price forecast for 2023?

6 brokers have issued 12 month price targets for Verona Pharma's stock. Their VRNA share price forecasts range from $27.00 to $32.00. On average, they anticipate the company's share price to reach $29.33 in the next year. This suggests a possible upside of 42.2% from the stock's current price.
View analysts price targets for VRNA or view top-rated stocks among Wall Street analysts.

How have VRNA shares performed in 2023?

Verona Pharma's stock was trading at $26.13 on January 1st, 2023. Since then, VRNA stock has decreased by 21.0% and is now trading at $20.63.
View the best growth stocks for 2023 here.

When is Verona Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our VRNA earnings forecast.

How were Verona Pharma's earnings last quarter?

Verona Pharma plc (NASDAQ:VRNA) issued its quarterly earnings results on Tuesday, March, 7th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.06. The firm had revenue of $0.46 million for the quarter.

What ETFs hold Verona Pharma's stock?

ETFs with the largest weight of Verona Pharma (NASDAQ:VRNA) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB), iShares Biotechnology ETF (IBB).

What other stocks do shareholders of Verona Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT).

When did Verona Pharma IPO?

(VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

What is Verona Pharma's stock symbol?

Verona Pharma trades on the NASDAQ under the ticker symbol "VRNA."

Who are Verona Pharma's major shareholders?

Verona Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (8.35%), Fairmount Funds Management LLC (3.80%), Frazier Life Sciences Management L.P. (3.72%), Jennison Associates LLC (1.36%), Samsara BioCapital LLC (0.92%) and Two Sigma Investments LP (0.69%). Insiders that own company stock include Anders Ullman, Claire Poll, David Zaccardelli, Kathleen A Rickard, Lisa Deschamps, Mark W Hahn, Mark W Hahn, Orbimed Advisors Llc and Patrick John Finn.
View institutional ownership trends.

How do I buy shares of Verona Pharma?

Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verona Pharma's stock price today?

One share of VRNA stock can currently be purchased for approximately $20.63.

How much money does Verona Pharma make?

Verona Pharma (NASDAQ:VRNA) has a market capitalization of $1.56 billion and generates $460,000.00 in revenue each year. The company earns $-68,700,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.

How can I contact Verona Pharma?

Verona Pharma's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The official website for the company is www.veronapharma.com. The company can be reached via phone at 011-44-0-2032834200 or via email at verona@argotpartners.com.

This page (NASDAQ:VRNA) was last updated on 3/27/2023 by MarketBeat.com Staff